within Pharmacolibrary.Drugs.ATC.L;

model L04AG10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.19 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,
    adminCount     = 1,
    Vd             = 0.0062,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Inebilizumab is a humanized monoclonal antibody directed against CD19, a protein expressed on B cells. It is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. It acts by depleting B cells involved in autoimmune pathophysiology.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported for adult NMOSD patients receiving intravenous inebilizumab in clinical trials.</p><h4>References</h4><ol><li><p>Agius, MA, et al., &amp; Flor, A (2019). Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. <i>Multiple sclerosis (Houndmills, Basingstoke, England)</i> 25(2) 235–245. DOI:<a href=&quot;https://doi.org/10.1177/1352458517740641&quot;>10.1177/1352458517740641</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29143550/&quot;>https://pubmed.ncbi.nlm.nih.gov/29143550</a></p></li><li><p>Yan, L, et al., &amp; Rees, WA (2022). Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders. <i>British journal of clinical pharmacology</i> 88(8) 3803–3812. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15332&quot;>10.1111/bcp.15332</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35332558/&quot;>https://pubmed.ncbi.nlm.nih.gov/35332558</a></p></li><li><p>Yan, L, et al., &amp; Rees, WA (2022). Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis. <i>Clinical pharmacokinetics</i> 61(3) 387–400. DOI:<a href=&quot;https://doi.org/10.1007/s40262-021-01071-5&quot;>10.1007/s40262-021-01071-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34718986/&quot;>https://pubmed.ncbi.nlm.nih.gov/34718986</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AG10;
